Financials data is unavailable for this security.
View more
Year on year Jiangsu Aidea Pharmaceutical Co Ltd grew revenues 68.44% from 244.22m to 411.36m while net income improved from a loss of 124.20m to a smaller loss of 76.07m.
Gross margin | 45.04% |
---|---|
Net profit margin | -31.64% |
Operating margin | -38.22% |
Return on assets | -6.45% |
---|---|
Return on equity | -9.82% |
Return on investment | -9.06% |
More ▼
Cash flow in CNYView more
In 2023, Jiangsu Aidea Pharmaceutical Co Ltd increased its cash reserves by 79.16%, or 98.00m. Cash Flow from Financing totalled 190.78m or 46.38% of revenues. In addition the company used 166.22m for operations while cash from investing totalled 73.44m.
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | 2.58 |
---|---|
Tangible book value per share | 2.10 |
More ▼
Balance sheet in CNYView more
Current ratio | 1.54 |
---|---|
Quick ratio | 1.13 |
Total debt/total equity | 0.3909 |
---|---|
Total debt/total capital | 0.281 |
More ▼
Growth rates in CNY
Year on year, growth in earnings per share excluding extraordinary items increased 38.87%.
Div yield(5 year avg) | 0.04% |
---|---|
Div growth rate (5 year) | -- |
Payout ratio (TTM) | -- |
EPS growth(5 years) | -- |
---|---|
EPS (TTM) vs TTM 1 year ago | -67.84 |
More ▼